A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB
Open Access
- 31 March 2023
- Vol. 11 (4), 778
- https://doi.org/10.3390/vaccines11040778
Abstract
Waves of breakthrough infections by SARS-CoV-2 Omicron subvariants currently pose a global challenge to the control of the COVID-19 pandemic. We previously reported a pVAX1-based DNA vaccine candidate, pAD1002, that encodes a receptor-binding domain (RBD) chimera of SARS-CoV-1 and Omicron BA.1. In mouse and rabbit models, pAD1002 plasmid induced cross-neutralizing Abs against heterologous sarbecoviruses, including SARS-CoV-1 and SARS-CoV-2 wildtype, Delta and Omicron variants. However, these antisera failed to block the recent emerging Omicron subvariants BF.7 and BQ.1. To solve this problem, we replaced the BA.1 RBD-encoding DNA sequence in pAD1002 with that of BA.4/5. The resulting construct, namely pAD1016, elicited SARS-CoV-1 and SARS-CoV-2 RBD-specific IFN-γ+ cellular responses in BALB/c and C57BL/6 mice. More importantly, pAD1016 vaccination in mice, rabbits and pigs generated serum Abs capable of neutralizing pseudoviruses representing multiple SARS-CoV-2 Omicron subvariants including BA.2, BA.4/5, BF.7, BQ.1 and XBB. As a booster vaccine for inactivated SARS-CoV-2 virus preimmunization in mice, pAD1016 broadened the serum Ab neutralization spectrum to cover the Omicron BA.4/5, BF7 and BQ.1 subvariants. These preliminary data highlight the potential benefit of pAD1016 in eliciting neutralizing Abs against broad-spectrum Omicron subvariants in individuals previously vaccinated with inactivated prototype SARS-CoV-2 virus and suggests that pAD1016 is worthy of further translational study as a COVID-19 vaccine candidate.Funding Information
- Ministry of Science and Technology of China (2021YFC2302500)
This publication has 30 references indexed in Scilit:
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunityCell, 2021
- The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and AntigenicityCell, 2020
- A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2Nature, 2020
- Immunogenicity of a DNA vaccine candidate for COVID-19Nature Communications, 2020
- Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2Cell, 2020
- The immunological anatomy of the skinNature Reviews Immunology, 2018
- Human Epidermal Langerhans Cells Maintain Immune Homeostasis in Skin by Activating Skin Resident Regulatory T CellsImmunity, 2012
- DNA vaccines: an historical perspective and view to the futureImmunological Reviews, 2010
- Murine epidermal Langerhans cells and langerin-expressing dermal dendritic cells are unrelated and exhibit distinct functionsProceedings of the National Academy of Sciences of the United States of America, 2009
- DNA Vaccines: Immunology, Application, and OptimizationAnnual Review of Immunology, 2000